December 22, 2016
Ono Pharmaceutical has shed its sales estimate for its immune checkpoint inhibitor Opdivo (nivolumab) for FY2016, bracing for a planned 50% price cut in February and an anticipated rival launch, the company said on December 21. For the year ending...read more